{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T07:18:39Z","timestamp":1782631119327,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012465","name":"Dalian Medical University","doi-asserted-by":"publisher","award":["JCHZ2023021"],"award-info":[{"award-number":["JCHZ2023021"]}],"id":[{"id":"10.13039\/501100012465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.intimp.2024.112569","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T17:15:50Z","timestamp":1719940550000},"page":"112569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Identification and validation of sialyltransferase ST3Gal5 in bladder cancer through bioinformatics and experimental analysis"],"prefix":"10.1016","volume":"138","author":[{"given":"Yuli","family":"Jian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1612-4190","authenticated-orcid":false,"given":"Abdullah","family":"Al-danakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0050-3794","authenticated-orcid":false,"given":"Shujing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.intimp.2024.112569_b0005","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.intimp.2024.112569_b0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1053\/j.semnuclmed.2020.02.006","article-title":"Targets for therapy of bladder cancer","volume":"50","author":"Seidl","year":"2020","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.intimp.2024.112569_b0015","doi-asserted-by":"crossref","unstructured":"H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: Cancer J. Clin., 2021, 71(3):209-249.","DOI":"10.3322\/caac.21660"},{"issue":"110393","key":"10.1016\/j.intimp.2024.112569_b0020","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed. Pharmacother. = Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.intimp.2024.112569_b0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.acuro.2020.08.003","article-title":"Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)","volume":"45","author":"\u00c1lvarez-Maestro","year":"2021","journal-title":"Actas Urol. Esp."},{"key":"10.1016\/j.intimp.2024.112569_b0030","doi-asserted-by":"crossref","unstructured":"V.G. Patel, W.K. Oh, M.D. Galsky, Treatment of muscle-invasive and advanced bladder cancer in 2020. CA: Cancer J. Clin., 2020, 70(5):404-423.","DOI":"10.3322\/caac.21631"},{"key":"10.1016\/j.intimp.2024.112569_b0035","article-title":"Effect of NCOR1 mutations on immune microenvironment and efficacy of immune checkpoint inhibitors in patient with bladder cancer","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Immunol."},{"issue":"6 Suppl 1","key":"10.1016\/j.intimp.2024.112569_b0040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112569_b0045","first-page":"4","article-title":"On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database","volume":"1473","author":"Apweiler","year":"1999","journal-title":"BBA"},{"issue":"9","key":"10.1016\/j.intimp.2024.112569_b0050","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.112569_b0055","article-title":"Altered glycosylation in cancer: A promising target for biomarkers and therapeutics","volume":"1875","author":"Thomas","year":"2021","journal-title":"Biochim. Biophys. Acta"},{"issue":"6","key":"10.1016\/j.intimp.2024.112569_b0060","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s10719-016-9697-8","article-title":"A functional splice variant of the human Golgi CMP-sialic acid transporter","volume":"33","author":"Salinas-Mar\u00edn","year":"2016","journal-title":"Glycoconj. J."},{"issue":"8","key":"10.1016\/j.intimp.2024.112569_b0065","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/glycob\/5.8.741","article-title":"1994, the year of sialyltransferases","volume":"5","author":"Harduin-Lepers","year":"1995","journal-title":"Glycobiology"},{"issue":"4\u20135","key":"10.1016\/j.intimp.2024.112569_b0070","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/pmic.201300387","article-title":"Cell surface protein glycosylation in cancer","volume":"14","author":"Christiansen","year":"2014","journal-title":"Proteomics"},{"key":"10.1016\/j.intimp.2024.112569_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118670","article-title":"The role of sialyltransferases in gynecological malignant tumors","volume":"263","author":"Zhang","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2024.112569_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.799861","article-title":"The Distinct Roles of Sialyltransferases in Cancer Biology and Onco-Immunology","volume":"12","author":"Hugonnet","year":"2021","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112569_b0085","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41419-018-1101-0","article-title":"Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-\u03b21-induced EMT and confers paclitaxel resistance in ovarian cancer","volume":"9","author":"Wu","year":"2018","journal-title":"Cell Death Dis."},{"issue":"13","key":"10.1016\/j.intimp.2024.112569_b0090","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-22-3260","article-title":"Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer","volume":"83","author":"Cao","year":"2023","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.intimp.2024.112569_b0095","doi-asserted-by":"crossref","first-page":"10078","DOI":"10.7150\/thno.48711","article-title":"Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancer","volume":"10","author":"Dalangood","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.intimp.2024.112569_b0100","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1038\/s41467-020-19575-2","article-title":"ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL","volume":"11","author":"Pietrobono","year":"2020","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.intimp.2024.112569_b0105","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbaexp.2006.07.001","article-title":"Human GM3 synthase: a new mRNA variant encodes an NH2-terminal extended form of the protein","volume":"1759","author":"Berselli","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"16","key":"10.1016\/j.intimp.2024.112569_b0110","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.2174\/0929867325666180129100619","article-title":"Ganglioside GM3 and its role in cancer","volume":"26","author":"Zheng","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2024.112569_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10719-014-9572-4","article-title":"GM3 and cancer","volume":"32","author":"Hakomori","year":"2015","journal-title":"Glycoconj J."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2024.112569_b0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.seminoncol.2018.04.003","article-title":"GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy","volume":"45","author":"Labrada","year":"2018","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.intimp.2024.112569_b0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-4598-9-3","article-title":"Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer","volume":"9","author":"Kim","year":"2010","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2024.112569_b0130","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.112569_b0135","first-page":"1973","article-title":"The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment","volume":"6","author":"Yang","year":"2021","journal-title":"Bioact. Mater."},{"issue":"6","key":"10.1016\/j.intimp.2024.112569_b0140","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur. Urol."},{"issue":"10364","key":"10.1016\/j.intimp.2024.112569_b0145","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet (london, England)"},{"issue":"8","key":"10.1016\/j.intimp.2024.112569_b0150","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s43018-022-00405-x","article-title":"Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1","volume":"3","author":"Mabe","year":"2022","journal-title":"Nat. Cancer"},{"issue":"26","key":"10.1016\/j.intimp.2024.112569_b0155","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1073\/pnas.1523968113","article-title":"B-cell-independent sialylation of IgG","volume":"113","author":"Jones","year":"2016","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.intimp.2024.112569_b0160","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s40001-023-01496-7","article-title":"A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer","volume":"28","author":"Cao","year":"2023","journal-title":"Eur. J. Med. Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.112569_b0165","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ijc.33866","article-title":"Sialic acids in gynecological cancer development and progression: Impact on diagnosis and treatment","volume":"150","author":"Berghuis","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"41","key":"10.1016\/j.intimp.2024.112569_b0170","doi-asserted-by":"crossref","first-page":"21424","DOI":"10.1074\/jbc.M116.751503","article-title":"Induction of Glycosphingolipid GM3 Expression by Valproic Acid Suppresses Cancer Cell Growth","volume":"291","author":"Kawashima","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2024.112569_b0175","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3892\/ol.2020.11597","article-title":"Downregulation of ST3GAL5 is associated with muscle invasion, high grade and a poor prognosis in patients with bladder cancer","volume":"20","author":"Ouyang","year":"2020","journal-title":"Oncol. Lett."},{"issue":"4","key":"10.1016\/j.intimp.2024.112569_b0180","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10238-010-0130-5","article-title":"Analysis of differentially expressed genes in human rectal carcinoma using suppression subtractive hybridization","volume":"11","author":"Choi","year":"2011","journal-title":"Clin. Exp. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.112569_b0185","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/labinvest.2017.12","article-title":"MiRNA expression profiles reveal the involvement of miR-26a, miR-548l and miR-34a in hepatocellular carcinoma progression through regulation of ST3GAL5","volume":"97","author":"Cai","year":"2017","journal-title":"Laborat. Investigat.; J. Tech. Methods Pathol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112569_b0190","article-title":"Tumor hypoxia regulates ganglioside GM3 synthase, which contributes to oxidative stress resistance in malignant melanoma","volume":"1864","author":"Shimizu","year":"2020","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.intimp.2024.112569_b0195","article-title":"Identification of ST3GAL5 as a prognostic biomarker correlating with CD8(+) T cell exhaustion in clear cell renal cell carcinoma","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112569_b0200","doi-asserted-by":"crossref","unstructured":"Y.J. Liang, Y. Ding, S.B. Levery, M. Lobaton, K. Handa, S.I. Hakomori, Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells, Proc. Natl. Acad. Sci. USA 2013, 110(13):4968-4973.","DOI":"10.1073\/pnas.1302825110"},{"issue":"1","key":"10.1016\/j.intimp.2024.112569_b0205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2024.112569_b0210","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fimmu.2020.00784","article-title":"The tumor microenvironment in the response to immune checkpoint blockade therapies","volume":"11","author":"Petitprez","year":"2020","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112569_b0215","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11538-022-01095-3","article-title":"A hybrid discrete-continuum modelling approach to explore the impact of T-cell infiltration on anti-tumour immune response","volume":"84","author":"Almeida","year":"2022","journal-title":"Bull. Math. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112569_b0220","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12967-023-03949-3","article-title":"Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis","volume":"21","author":"Koll","year":"2023","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.intimp.2024.112569_b0225","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145666","article-title":"Tan TZ et al.: BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer","volume":"132","author":"Rouanne","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"7780","key":"10.1016\/j.intimp.2024.112569_b0230","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumour immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.intimp.2024.112569_b0235","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"issue":"14","key":"10.1016\/j.intimp.2024.112569_b0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147248","article-title":"Tumor escape phenotype in bladder cancer is associated with loss of HLA class I expression, T-cell exclusion and stromal changes","volume":"22","author":"Gil-Julio","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.112569_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.107164","article-title":"Glycosyltransferase-related prognostic and diagnostic biomarkers of uterine corpus endometrial carcinoma","volume":"163","author":"Wu","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.intimp.2024.112569_b0250","doi-asserted-by":"crossref","unstructured":"C.N. Sternberg, P. de Mulder, J.H. Schornagel, C. Theodore, S.D. Fossa, A.T. van Oosterom, J.A. Witjes, M. Spina, C.J. van Groeningen, B. Duclos, et al:, Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours, Eur. J. Cancer (Oxford, England : 1990) 2006, 42(1):50-54.","DOI":"10.1016\/j.ejca.2005.08.032"},{"issue":"18","key":"10.1016\/j.intimp.2024.112569_b0255","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924010907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924010907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T17:27:28Z","timestamp":1722360448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924010907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":51,"alternative-id":["S1567576924010907"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112569","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and validation of sialyltransferase ST3Gal5 in bladder cancer through bioinformatics and experimental analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112569"}}